Brokers Offer Predictions for TRVI Q2 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued on Wednesday, May 28th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $1.66 EPS.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04.

A number of other brokerages also recently issued reports on TRVI. Oppenheimer raised their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. D. Boral Capital reiterated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of Trevi Therapeutics in a research report on Tuesday, May 20th. B. Riley reaffirmed a "buy" rating and issued a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $18.63.

Trevi Therapeutics Price Performance

NASDAQ:TRVI traded down $0.46 during trading hours on Friday, hitting $5.86. The company's stock had a trading volume of 2,103,260 shares, compared to its average volume of 1,252,806. The stock has a fifty day simple moving average of $6.24 and a 200-day simple moving average of $4.91. The company has a market capitalization of $585.37 million, a P/E ratio of -13.32 and a beta of 0.62. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.48.

Hedge Funds Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TRVI. Point72 Asset Management L.P. acquired a new stake in Trevi Therapeutics during the fourth quarter worth $17,099,000. Octagon Capital Advisors LP acquired a new stake in Trevi Therapeutics during the first quarter worth $20,895,000. Frazier Life Sciences Management L.P. increased its stake in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Armistice Capital LLC acquired a new stake in Trevi Therapeutics during the first quarter worth $18,795,000. Finally, Woodline Partners LP increased its stake in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

Insider Activity at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by corporate insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.